SDGR on Nasdaq

Schrödinger

Logo: schrodinger.com4

American life sciences company

Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$255.9MRevenue, fiscal 20255
-$103.3MNet income, fiscal 20255
1990Founded1

Compare with Arvinas (United States), LIGAND PHARMACEUTICALS INC or Keros Therapeutics, Inc., or pick any stock.

  • TickerSDGR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York City1
  • Websitewww.schrodinger.com
  • Incorporated inDE6
  • Business address1540 Broadway, 24Th Floor, New York, Ny 100366
  • Filer categoryLarge accelerated filer6

See how the biggest companies compare on our leaderboards

Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

55.7%Gross margin5
-65.2%Operating margin5
-40.4%Net margin5
23.3%Revenue growth, 20255
-28.4%Return on equity5
$12.5MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Software Products And Services brought in 59% of the revenue Schrödinger broke down this way in fiscal 2025.

  1. Software Products And Services$199.5M559%up 11% from 2024
  2. Drug Discovery$56.4M517%up 107% from 2024
  3. Hosted Software$45.1M513%up 28% from 2024
  4. Maintenance$27.3M58%up 17% from 2024
  5. Professional Services$9.6M53%down 2% from 2024
Products and services by year
Products and services202320242025
Software Products And Services$159.1M$180.4M$199.5M
Drug Discovery$57.5M$27.2M$56.4M
Hosted Software$20.4M$35.3M$45.1M
Maintenance$23.1M$23.3M$27.3M
Professional Services$9.4M$9.8M$9.6M

Business segments

Software brought in 78% of the revenue Schrödinger broke down this way in fiscal 2025.

  1. Software$199.5M578%up 11% from 2024
  2. Drug Discovery$56.4M522%up 107% from 2024
Business segments by year
Business segments202320242025
Software$159.1M$180.4M$199.5M
Drug Discovery$57.5M$27.2M$56.4M

Regions

United States brought in 60% of the revenue Schrödinger broke down this way in fiscal 2025.

  1. United States$153.0M560%up 33% from 2024
  2. EMEA$75.2M529%up 14% from 2024
  3. APAC$26.2M510%up 1% from 2024
  4. Rest of the world$1.6M51%up 28% from 2024
Regions by year
Regions202320242025
United States$162.0M$114.9M$153.0M
EMEA$29.1M$65.7M$75.2M
APAC$24.6M$25.8M$26.2M
Rest of the world$1.0M$1.2M$1.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue39¢$113.3M
  • Research and development60¢$173.1M
  • Income tax0¢$939.0K

Out of $255.9M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending10¢$1.4M
  • Kept or used elsewhere90¢$12.5M

Out of $13.9M of cash from operations.5

Financial statements

Revenue89105$255.9M in 2025+199% since 2019
0$100.0M$200.0M$300.0M2019: $85.5M$85.5M20192020: $108.1M$108.1M2020+26%2021: $137.9M$137.9M2021+28%2022: $181.0M$181.0M2022+31%2023: $216.7M$216.7M2023+20%2024: $207.5M$207.5M2024−4%2025: $255.9M$255.9M2025+23%
Gross profit8119105$142.6M in 2025+190% since 2019
0$50.0M$100.0M$150.0M2019: $49.1M$49.1M20192020: $63.5M$63.5M2020+29%2021: $65.6M$65.6M2021+3%2022: $101.0M$101.0M2022+54%2023: $140.7M$140.7M2023+39%2024: $132.1M$132.1M2024−6%2025: $142.6M$142.6M2025+8%
Operating income8119105-$166.9M in 2025+331% since 2019
-$300.0M-$200.0M-$100.0M02019: -$38.7M-$38.7M20192020: -$60.9M-$60.9M2020+57%2021: -$111.4M-$111.4M2021+83%2022: -$146.8M-$146.8M2022+32%2023: -$177.4M-$177.4M2023+21%2024: -$209.3M-$209.3M2024+18%2025: -$166.9M-$166.9M2025−20%
Net income8119105-$103.3M in 2025+320% since 2019
-$200.0M-$100.0M0$100.0M2019: -$24.6M-$24.6M20192020: -$24.5M-$24.5M2020−0%2021: -$100.4M-$100.4M2021+310%2022: -$149.2M-$149.2M2022+49%2023: $40.7M$40.7M20232024: -$187.1M-$187.1M20242025: -$103.3M-$103.3M2025−45%

Every line of the income statement in the latest annual report, as filed.5

Period ending2025-12-312024-12-312023-12-31
Total revenues$255.9M$207.5M$216.7M
Total cost of revenues$113.3M$75.5M$76.0M
Gross profit$142.6M$132.1M$140.7M
Research and development$173.1M$201.8M$181.8M
Sales and marketing$41.0M$39.9M$37.2M
General and administrative$95.4M$99.7M$99.1M
Total operating expenses$309.5M$341.4M$318.1M
Loss from operations-$166.9M-$209.3M-$177.4M
Gain on equity investments$0$0$147.2M
Change in fair value of equity investments$48.2M$5.7M$53.5M
Other income$16.4M$17.9M$19.7M
Total other income$64.6M$23.6M$220.4M
(Loss) income before income taxes-$102.3M-$185.7M$42.9M
Income tax expense$939.0K$1.4M$2.2M
Net (loss) income-$103.3M-$187.1M$40.7M
Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share)-$1.41-$2.57$0.57
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)73.4M shares72.7M shares71.8M shares
Net (loss) income per share of common and limited common stockholders, diluted (in USD per share)-$1.41-$2.57$0.54
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)73.4M shares72.7M shares75.0M shares

Compare Schrödinger with another company

The story

Founded by Richard A. Friesner and William Andrew Goddard III in 1990.1

Leadership

Who has led Schrödinger, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Products and brands

Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. The company's products include molecular modeling programs in life science, and Materials Science, and an Enterprise Informatics Platform named LiveDesign, which is intended to facilitate communication among interdisciplinary research teams.

Small Molecular Discovery

Structure Prediction & Target Enablement

Hit Discovery

Hit-to-Lead & Lead Optimization

Read the full text

Drug Formulation

Biologics Discovery

Antibody Design

Peptide Discovery

Enzyme Engineering

Material Science Applications

Organic Electronics

Polymeric Materials

Consumer Packaged Goods

Catalysis & Reactivity

Thin Film Processing Energy Capture & Storage

Pharmaceutical Formulations & Delivery

Metals, Alloys & Ceramics

In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects.

Schrödinger software licenses are available to academic institutions for education and not-for-profit research.

From Wikipedia’s article on Schrödinger, Inc., shared under CC BY-SA 4.0.7

Timeline

  1. 1990Founded Founded1

Recent filings

  1. Sep 21, 20264
  2. Sep 17, 2026144
  3. Aug 5, 20268-K
  4. Aug 5, 202610-Q
  5. Aug 5, 2026S-8
  6. Jul 17, 20264
  7. Jul 16, 2026144
  8. Jul 1, 2026144
  9. Jun 29, 20268-K
  10. Jun 29, 20264
  11. Jun 23, 20268-K
  12. Jun 23, 20264
  13. Jun 23, 20264
  14. Jun 23, 20264
  15. Jun 23, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteSchrödinger logo
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16